Oculus imaging device approved by FDA

Article

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.

The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
Related Content
An eye slightly obscured by DNA helix strands. Image credit: ©natali_mis – stock.adobe.com

May is Inherited Retinal Disease Genetic Testing Awareness Month, Prevent Blindness expands on previous weeklong campaign

April 26th 2024
Article

During the month of May, Prevent Blindness will offer fact sheets, videos and other resources for IRD education

Hemoglobin molecule structure, rendered in pink and purple. Generative AI. Image credit: ©Electro Unicorn – stock.adobe.com

TEASE-3 study: Positive interim data are reported for Stargardt drug

April 25th 2024
Article

Gildeuretinol halts Stargardt disease progression, study results indicate

A researcher sits at a computer. Image credit: ©lightpoet – stock.adobe.com

Interactive vision simulator illustrates the vision loss caused by retinal diseases

April 23rd 2024
Article

The online tool shows vision loss simulations for diabetic macular oedema, diabetic retinopathy, age-related macular degeneration and other retinal diseases

Professor Ramin Tadayoni, MD, PhD. Image courtesy of EURETINA

Retina community mourns sudden loss of Ramin Tadayoni, MD, PhD

April 22nd 2024
Article

Prof Tadayoni was a much-admired leader, researcher, surgeon and EURETINA President

A cell in amniotic fluid. Image credit: ©Icruci – stock.adobe.com

Amniotic membrane could move the needle outside of the operating room

April 19th 2024
Article

The tissue serves as a testing ground for outpatient ocular therapies

Concept image for an exhibition hall crowded with people. Image credit: ©arhendrix – stock.adobe.com

Clinicians and researchers don’t shy away from hot topics in the field

April 18th 2024
Article

The 15th annual Congress on Controversies in Ophthalmology heads to Athens, Greece

© 2024 MJH Life Sciences

All rights reserved.